New hope for lung cancer patients when first immunotherapy fails
NCT ID NCT07330596
Summary
This study is testing whether adding a new two-in-one immunotherapy drug (QL1706) to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer. It is for patients whose cancer has started growing again after their first treatment with a different type of immunotherapy. The goal is to see if this new combination can better control the cancer's growth and extend life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui cancer hospital
RECRUITINGHefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.